{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:05:09Z","timestamp":1777550709345,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"DOI":"10.7759\/cureus.61496","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T15:59:09Z","timestamp":1717257549000},"source":"Crossref","is-referenced-by-count":2,"title":["Real-World Data on the Effectiveness and Safety of Filgotinib for Ulcerative Colitis in Japanese Patients: A Single-Center Experience"],"prefix":"10.7759","author":[{"given":"Takahito","family":"Toba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Karashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanako","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurie","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi T","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, et al.. Ulcerative colitis. Nat Rev Dis Primers. 2020, 6:74. 10.1038\/s41572-020-0205-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103017","article-title":"The influence of cytokines on the complex pathology of ulcerative colitis","volume":"21","author":"Nakase H","year":"2022","unstructured":"Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022, 21:103017. 10.1016\/j.autrev.2021.103017","journal-title":"Autoimmun Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas A","year":"2020","unstructured":"Salas A, Hernandez-Rocha C, Duijvestein M, et al.. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020, 17:323-37. 10.1038\/s41575-020-0273-0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan BG","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV, et al.. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021, 397:2372-84. 10.1016\/S0140-6736(21)00666-8","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab206","article-title":"Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis","volume":"16","author":"D'Amico F","year":"2022","unstructured":"D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis. 2022, 16:835-44. 10.1093\/ecco-jcc\/jjab206","journal-title":"J Crohns Colitis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2200931","article-title":"Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors","volume":"24","author":"Goetsch A","year":"2023","unstructured":"Goetsch A, D'Amico F, Allocca M, et al.. Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors. Expert Opin Pharmacother. 2023, 24:849-61. 10.1080\/14656566.2023.2200931","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01509-1","article-title":"Comparative efficacy of advanced treatments in biologic-na\u00efve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis","volume":"45","author":"Lu X","year":"2023","unstructured":"Lu X, Jarrett J, Sadler S, Tan M, Dennis J, Jairath V. Comparative efficacy of advanced treatments in biologic-na\u00efve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis. Int J Clin Pharm. 2023, 45:330-41. 10.1007\/s11096-022-01509-1","journal-title":"Int J Clin Pharm"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13622","article-title":"Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis","volume":"47","author":"Li Y","year":"2022","unstructured":"Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. J Clin Pharm Ther. 2022, 47:851-9. 10.1111\/jcpt.13622","journal-title":"J Clin Pharm Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis","volume":"5","author":"Panaccione R","year":"2023","unstructured":"Panaccione R, Collins EB, Melmed GY, et al.. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis 360. 2023, 5:otad009. 10.1093\/crocol\/otad009","journal-title":"Crohns Colitis 360"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2069562","article-title":"Emerging therapies for ulcerative colitis","volume":"18","author":"Hanzel J","year":"2022","unstructured":"Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol. 2022, 18:513-24. 10.1080\/1744666X.2022.2069562","journal-title":"Expert Rev Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase H","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al.. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021, 56:489-526. 10.1007\/s00535-021-01784-1","journal-title":"J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner D","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al.. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021, 160:1570-83. 10.1053\/j.gastro.2020.12.031","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060081","article-title":"Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study","volume":"12","author":"Matsuoka K","year":"2022","unstructured":"Matsuoka K, Nagano K, Nagasaki S, Murata Y, Hisamatsu T. Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study. BMJ Open. 2022, 12:e060081. 10.1136\/bmjopen-2021-060081","journal-title":"BMJ Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2021.00143","article-title":"Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b\/3 SELECTION trial","volume":"21","author":"Hibi T","year":"2023","unstructured":"Hibi T, Motoya S, Hisamatsu T, et al.. Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b\/3 SELECTION trial. Intest Res. 2023, 21:110-25. 10.5217\/ir.2021.00143","journal-title":"Intest Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad039","article-title":"Efficacy of filgotinib in patients with ulcerative colitis by line of therapy in the phase 2b\/3 SELECTION trial","volume":"17","author":"Dotan I","year":"2023","unstructured":"Dotan I, Feagan BG, Taliadouros V, et al.. Efficacy of filgotinib in patients with ulcerative colitis by line of therapy in the phase 2b\/3 SELECTION trial. J Crohns Colitis. 2023, 17:1207-16. 10.1093\/ecco-jcc\/jjad039","journal-title":"J Crohns Colitis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2023.2195522","article-title":"Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment","volume":"46","author":"Nakase H","year":"2023","unstructured":"Nakase H. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment. Immunol Med. 2023, 46:121-30. 10.1080\/25785826.2023.2195522","journal-title":"Immunol Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad173","article-title":"Janus kinase inhibitors differentially inhibit specific cytokine signals in the mesenteric lymph node cells of inflammatory bowel disease patients","volume":"18","author":"Hindmarch DC","year":"2024","unstructured":"Hindmarch DC, Malashanka S, Shows DM, Clarke AS, Lord JD. Janus kinase inhibitors differentially inhibit specific cytokine signals in the mesenteric lymph node cells of inflammatory bowel disease patients. J Crohns Colitis. 2024, 18:628-37. 10.1093\/ecco-jcc\/jjad173","journal-title":"J Crohns Colitis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad201","article-title":"Impact of concomitant thiopurine on the efficacy and safety of filgotinib in patients with ulcerative colitis: post hoc analysis of the phase 2b\/3 SELECTION study","author":"Watanabe K","year":"2023","unstructured":"Watanabe K, Peyrin-Biroulet L, Danese S, et al.. Impact of concomitant thiopurine on the efficacy and safety of filgotinib in patients with ulcerative colitis: post hoc analysis of the phase 2b\/3 SELECTION study. J Crohns Colitis. 2023,  jjad201. 10.1093\/ecco-jcc\/jjad201","journal-title":"J Crohns Colitis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes Zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop KL","year":"2018","unstructured":"Winthrop KL, Melmed GY, Vermeire S, et al.. Herpes Zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018, 24:2258-65. 10.1093\/ibd\/izy131","journal-title":"Inflamm Bowel Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez P","year":"2023","unstructured":"N\u00fa\u00f1ez P, Quera R, Yarur AJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases. Drugs. 2023, 83:299-314. 10.1007\/s40265-023-01840-5","journal-title":"Drugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad187","article-title":"Real-world cohort study on the effectiveness and safety of filgotinib use in ulcerative colitis","author":"Gros B","year":"2023","unstructured":"Gros B, Goodall M, Plevris N, et al.. Real-world cohort study on the effectiveness and safety of filgotinib use in ulcerative colitis. J Crohns Colitis. 2023,  jjad187. 10.1093\/ecco-jcc\/jjad187","journal-title":"J Crohns Colitis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.4457","article-title":"AB0494 Filgotinib (GLPG0634), a selective JAK1 inhibitor, shows similar PK and PD profiles in Japanese and Caucasian healthy volunteers","volume":"74","author":"Namour F","year":"2015","unstructured":"Namour F, Vayssi\u00e8re B, Galien R, et al.. AB0494 Filgotinib (GLPG0634), a selective JAK1 inhibitor, shows similar PK and PD profiles in Japanese and Caucasian healthy volunteers. Ann Rheum Dis. 2015, 74:1063-4. 10.1136\/annrheumdis-2015-eular.4457","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/258777-real-world-data-on-the-effectiveness-and-safety-of-filgotinib-for-ulcerative-colitis-in-japanese-patients-a-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T15:59:12Z","timestamp":1717257552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/258777-real-world-data-on-the-effectiveness-and-safety-of-filgotinib-for-ulcerative-colitis-in-japanese-patients-a-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.61496","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}